A Randomized, Open Label, Long-Term, Multi-Center Study of the Safety of Medisorb® Naltrexone
Overview
- Phase
- Phase 3
- Intervention
- Medisorb naltrexone 380 mg
- Conditions
- Alcoholism
- Sponsor
- Alkermes, Inc.
- Enrollment
- 436
- Primary Endpoint
- Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
This was a Phase 3 multicenter randomized, open-label, safety study assessing the safety of repeat doses of Medisorb® naltrexone 380 mg (VIVITROL®) administered for up to 1 year to adults with alcohol and/or opioid dependence as defined by Diagnostic and Statistical Manual of Mental Health Disorders (DSM-IV) criteria. Eligible subjects were randomized in a 6:1 ratio to receive 1 of the following regimens: a single intramuscular (IM) injection of VIVITROL administered once every 4 weeks or oral naltrexone 50 mg administered daily.
Detailed Description
Safety evaluations included physical examinations, electrocardiograms (ECGs), laboratory measures (including plasma concentrations of naltrexone and 6β-naltrexol), assessments of injection sites, and adverse events (AEs). All subjects received psychosocial support at each study visit for the duration of the study, with interim telephone contact 2 weeks after each monthly visit.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Current diagnosis of DSM-IV alcohol dependence and/or diagnosis of DSM-IV opiate dependence within 3 months prior to screening
- •18 years or older
- •Desire to seek treatment for alcohol and/or opiate abuse/dependence
- •Agree to use contraception for the study duration if of childbearing potential
- •Written informed consent and willingness to perform study procedures
- •Stable address and phone and at least 1 source of contact information (eg, family member, significant other)
Exclusion Criteria
- •Presence of opiates in the urine (as determined by urine drug test) on Day 0 prior to naltrexone treatment
- •Clinically significant medical/psychological condition or abnormality at screening (ie, physical examination, electrocardiogram \[ECG\], hematology or blood chemistry evaluation, or urinalysis findings)
- •Clinically significant active hepatitis or hepatic failure evidenced by 1 of the following: aspartate transaminase (AST) or alanine transaminase (ALT) higher than 3 times the upper limit of normal (3xULN), hyperbilirubinemia (bilirubin \>10% above ULN), creatine phosphokinase (CPK) higher than 10xULN, prolonged prothrombin time(international normalized ratio ≥1.7), ascites, or esophageal variceal disease
- •Manifestation of suicidal ideation, psychotic symptoms (including significant violent behavior), or psychiatric disorders that would compromise ability to complete the study
- •Participation in a formal methadone program currently or within prior 3 years
- •More than 2 prior medically supervised detoxification treatments in prior 3 years
- •Pregnancy or lactation
- •Current prescribed opiate therapy, or receipt of opiates within 7 days prior to study drug dosing, or ongoing medical condition likely to require prescribed opiate therapy during study period
- •Failed naloxone challenge on Day 0 (the challenge could be repeated up to 2 times, with at least 24 hours between attempts)
- •Participation in a clinical trial within 30 days of screening
Arms & Interventions
Medisorb naltrexone 380 mg (VIVITROL)
Intervention: Medisorb naltrexone 380 mg
Oral naltrexone 50 mg
Intervention: Oral naltrexone 50 mg
Outcomes
Primary Outcomes
Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study
Time Frame: up to 1 year
A TEAE was defined as any adverse event (AE) that started or worsened on or after the administration of the first dose of study medication through 30 days after the end of study treatment.